Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 96,699
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12616651 | Topical lipolysis composition and methods | 🖼🧊📄§ | 2026-05-05 | 2041-10-07 | 0 | 31 |
| 12616650 | Radiation sensitizer of anti-cancer chemotherapy sensitizer | 🖼🧊📄§ | 2026-05-05 | 2040-07-23 | 0 | 31 |
| 12616660 | Compressible and free-flow co-agglomerates of crystalline mannitol and granular starch | 🖼🧊📄§ | 2026-05-05 | 2041-09-24 | 0 | 31 |
| 12616657 | Cell-targeted nanoparticles to inhibit RNA cargo | 🖼🧊📄§ | 2026-05-05 | 2041-02-26 | 0 | 31 |
| 12616655 | Topical antibiotic containing pharmaceutical composition for bacterial infections and wound healing | 🖼🧊📄§ | 2026-05-05 | 2040-10-19 | 0 | 31 |
| 12616659 | Therapeutic agent nanoparticles and methods of preparation | 🖼🧊📄§ | 2026-05-05 | 2043-05-24 | 0 | 31 |
| 12616747 | Stabilized beta-coronavirus antigens | 🖼🧊📄§ | 2026-05-05 | 2042-12-02 | 0 | 31 |
| 12616727 | Compositions, systems, and methods for improving health | 🖼🧊📄§ | 2026-05-05 | 2043-06-29 | 0 | 31 |
| 12616726 | Probiotic supplement for metabolic health | 🖼🧊📄§ | 2026-05-05 | 2044-03-27 | 0 | 31 |
| 12616712 | Sting agonist comprising exosomes for treating neuroimmunological disorders | 🖼🧊📄§ | 2026-05-05 | 2040-09-24 | 0 | 31 |
| 12616701 | Solid state forms of Resmetirom | 🖼🧊📄§ | 2026-05-05 | 2041-10-19 | 0 | 31 |
| 12616693 | Bromocriptine formulations | 🖼🧊📄§ | 2026-05-05 | 2043-04-26 | 0 | 31 |
| 12616692 | Method of achieving HIV viral remission using long-acting antiretroviral agents | 🖼🧊📄§ | 2026-05-05 | 2041-06-30 | 0 | 31 |
| 12616671 | Use of rigosertib to treat RNA virus infections | 🖼🧊📄§ | 2026-05-05 | 2041-05-28 | 0 | 31 |
| 12618048 | Dual CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2041-07-30 | 0 | 31 |
| 12617816 | Composition and method for in vivo assay of opioid receptors | 🖼🧊📄§ | 2026-05-05 | 2040-11-11 | 0 | 31 |
| 12617773 | Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators | 🖼🧊📄§ | 2026-05-05 | 2041-04-30 | 0 | 31 |
| 12617772 | Hydroxypyridine HSD17B13 inhibitors and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-04-04 | 0 | 31 |
| 12617774 | Substituted indole compounds and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2045-05-30 | 0 | 31 |
| 12617854 | Humanized or chimeric CD3 antibodies | 🖼🧊📄§ | 2026-05-05 | 2042-05-09 | 0 | 31 |
| 12618055 | Hyaluronidase variants with improved stability and pharmaceutical composition comprising the same | 🖼🧊📄§ | 2026-05-05 | 2041-01-25 | 0 | 31 |
| 12617853 | Low pH pharmaceutical composition comprising T cell engaging antibody constructs | 🖼🧊📄§ | 2026-05-05 | 2038-02-02 | 0 | 31 |
| 12616720 | Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo | 🖼🧊📄§ | 2026-05-05 | 2042-06-10 | 0 | 31 |
| 12617887 | Resin composition for stereolithography | 🖼🧊📄§ | 2026-05-05 | 2041-02-09 | 0 | 31 |
| 12617873 | Method of purifying polysaccharides | 🖼🧊📄§ | 2026-05-05 | 2040-11-30 | 0 | 31 |
| 12617857 | Chemokine receptor 4 (CXCR4) antagonist antibodies | 🖼🧊📄§ | 2026-05-05 | 2041-04-22 | 0 | 31 |
| 12620489 | Method for determining the risk to develop type 1 diabetes | 🖼🧊📄§ | 2026-05-05 | 2038-06-27 | 0 | 31 |
| 12617903 | Process for producing a composition comprising a crosslinked hydrogel | 🖼🧊📄§ | 2026-05-05 | 2040-12-08 | 0 | 31 |
| 12617827 | Self-assembling peptide | 🖼🧊📄§ | 2026-05-05 | 2041-07-29 | 0 | 31 |
| 12616683 | Combination therapy for the treatment of gastrointestinal stromal tumors | 🖼🧊📄§ | 2026-05-05 | 2044-04-10 | 0 | 31 |
| 12616756 | Dimeric antibodies | 🖼🧊📄§ | 2026-05-05 | 2044-08-16 | 0 | 31 |
| 12616704 | Cannabichromene formulation for pain management | 🖼🧊📄§ | 2026-05-05 | 2041-03-31 | 0 | 31 |
| 12616757 | Compositions and methods for correction of heritable ocular disease | 🖼🧊📄§ | 2026-05-05 | 2041-04-14 | 0 | 31 |
| 12617835 | Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease | 🖼🧊📄§ | 2026-05-05 | 2040-06-05 | 0 | 31 |
| 12616661 | Composition for type II diabetics and for use in providing sustained energy release over time | 🖼🧊📄§ | 2026-05-05 | 2039-03-07 | 0 | 31 |
| 12616755 | Antifungal quercetin conjugates, methods of preparation and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2045-10-08 | 0 | 31 |
| 12616652 | Lenses for treating ocular diseases and preparation method thereof | 🖼🧊📄§ | 2026-05-05 | 2042-12-29 | 0 | 31 |
| 12616745 | Influenza virus backbone | 🖼🧊📄§ | 2026-05-05 | 2040-06-05 | 0 | 31 |
| 12616733 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | 🖼🧊📄§ | 2026-05-05 | 2041-02-10 | 0 | 31 |
| 12616714 | Enhanced oligonucleotides for modulating FUBP1 expression | 🖼🧊📄§ | 2026-05-05 | 2041-06-25 | 0 | 31 |
| 12616749 | Methods for treatment of psoriasis with an anti-oxLDL antibody | 🖼🧊📄§ | 2026-05-05 | 2044-06-21 | 0 | 31 |
| 12616685 | Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates | 🖼🧊📄§ | 2026-05-05 | 2041-05-26 | 0 | 31 |
| 12616782 | Use of mitochondria to treat and/or prevent tendon injury or its related disease | 🖼🧊📄§ | 2026-05-05 | 2041-03-19 | 0 | 31 |
| 12616721 | Stratified squamous epithelial cell normal differentiation and maturation promoting agent, epithelial disease therapeutic agent, and stratified squamous epithelial cell normal differentiation and maturation promoting method | 🖼🧊📄§ | 2026-05-05 | 2039-01-11 | 0 | 31 |
| 12616751 | Photosensitizing antibody-fluorophore conjugates | 🖼🧊📄§ | 2026-05-05 | 2042-06-15 | 0 | 31 |
| 12616696 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | 🖼🧊📄§ | 2026-05-05 | 2041-03-26 | 0 | 31 |
| 12616663 | Plant-derived exosome-like nanoparticles inhibit bacterial pathogenicity | 🖼🧊📄§ | 2026-05-05 | 2040-03-02 | 0 | 31 |
| 12617838 | Auto/allo-immune defense receptors for the selective targeting of activated pathogenic T cells and NK cells | 🖼🧊📄§ | 2026-05-05 | 2039-04-25 | 0 | 31 |
| 12617848 | Methods of treating ocular pathologies using bifunctional molecules that target growth factors | 🖼🧊📄§ | 2026-05-05 | 2041-11-08 | 0 | 31 |
| 12617834 | Composition of NY-ESO-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules | 🖼🧊📄§ | 2026-05-05 | 2039-09-04 | 0 | 31 |